Searched over 200M research papers
10 papers analyzed
Some studies suggest high-dose folic acid supplementation during pregnancy can reduce certain adverse outcomes and homocysteine levels, while other studies indicate it does not prevent pre-eclampsia and may increase the risk of gestational hypertension.
20 papers analyzed
Folic acid (FA) is a synthetic form of folate, a B-vitamin essential for cell development and biochemical reactions, including DNA synthesis and the remethylation of homocysteine to methionine. It is widely recommended for women who are planning or capable of pregnancy to prevent neural tube defects (NTDs) in the fetus. However, the optimal dose of FA supplementation during pregnancy remains a topic of ongoing research and debate.
The standard recommendation for FA supplementation is 0.4 mg/day, which has been shown to significantly reduce the risk of NTDs. A study comparing 4.0 mg to 0.4 mg of FA found no significant difference in the occurrence of congenital malformations (CMs) between the two groups. However, the higher dose was associated with a lower occurrence of other adverse pregnancy outcomes.
Pre-eclampsia is a serious pregnancy-related hypertensive disorder. Research has shown mixed results regarding the efficacy of high-dose FA in preventing pre-eclampsia. One study found no significant difference in the incidence of pre-eclampsia between women taking 4.0 mg/day of FA and those taking a placebo . Another study suggested that high-dose FA could reduce homocysteine levels, which are associated with pre-eclampsia, but did not find a significant impact on blood pressure.
High-dose FA supplementation has been linked to improved birth outcomes. A study in Crete found that 5 mg/day of FA was associated with a reduced risk of preterm birth, low birth weight, and small for gestational age (SGA) neonates. This suggests that higher doses of FA may have protective effects on fetal growth and development.
The pharmacokinetics of FA during pregnancy indicate that higher doses lead to increased red blood cell (RBC) folate concentrations over time. A study comparing 1.1 mg to 5 mg of FA found that the higher dose resulted in a more significant increase in RBC folate levels. Another study within the Folic Acid Clinical Trial (FACT) showed that high-dose FA increased maternal serum folate but not RBC folate, suggesting tissue saturation.
High-dose FA has been shown to reduce homocysteine levels, which are inversely related to folate intake and associated with adverse pregnancy outcomes. Lower homocysteine levels were observed in women taking higher doses of FA, which could potentially reduce the risk of hypertensive disorders .
While FA supplementation is generally considered safe, there is concern about exceeding the upper tolerable limit of 1000 mcg/day, especially in countries with mandatory food fortification programs. A systematic review found that women taking FA supplements in such countries often exceed this limit, which could have implications for folic acid absorption and metabolism.
The appropriate dose of folic acid during pregnancy is crucial for preventing neural tube defects and potentially improving other pregnancy outcomes. While higher doses of FA (4.0 mg or more) may offer additional benefits such as reduced adverse pregnancy outcomes and improved fetal growth, they do not appear to significantly prevent pre-eclampsia. Further research is needed to clarify the optimal dosing strategy, especially considering the potential risks of exceeding the upper tolerable limit.
Most relevant research papers on this topic